Quest Diagnostics (DGX) Competitors

Quest Diagnostics logo
$256.93 -5.28 (-2.01%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

DGX vs. HSIC, MEDP, AMN, LH, and CVS

Should you buy Quest Diagnostics stock or one of its competitors? Quest Diagnostics's main competitors and comparable companies include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), and CVS Health (CVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Quest Diagnostics compare to Henry Schein?

Quest Diagnostics (NYSE:DGX) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Quest Diagnostics has a net margin of 9.53% compared to Henry Schein's net margin of 3.07%. Henry Schein's return on equity of 16.39% beat Quest Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Quest Diagnostics9.53% 16.21% 7.41%
Henry Schein 3.07%16.39%5.58%

Quest Diagnostics presently has a consensus target price of $248.70, indicating a potential downside of 4.96%. Henry Schein has a consensus target price of $93.57, indicating a potential upside of 10.14%. Given Henry Schein's higher possible upside, analysts clearly believe Henry Schein is more favorable than Quest Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quest Diagnostics
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.56
Henry Schein
1 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by insiders. Comparatively, 0.9% of Henry Schein shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Quest Diagnostics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Quest Diagnostics has higher earnings, but lower revenue than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$11.04B2.61$992M$10.0426.06
Henry Schein$13.18B0.71$398M$3.6523.28

In the previous week, Quest Diagnostics had 19 more articles in the media than Henry Schein. MarketBeat recorded 28 mentions for Quest Diagnostics and 9 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 0.22 beat Henry Schein's score of 0.13 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quest Diagnostics
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Henry Schein
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Quest Diagnostics beats Henry Schein on 10 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to Medpace?

Medpace (NASDAQ:MEDP) and Quest Diagnostics (NYSE:DGX) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Medpace has a net margin of 18.24% compared to Quest Diagnostics' net margin of 9.53%. Medpace's return on equity of 99.76% beat Quest Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medpace18.24% 99.76% 24.47%
Quest Diagnostics 9.53%16.21%7.41%

Medpace presently has a consensus price target of $649.27, suggesting a potential upside of 0.17%. Quest Diagnostics has a consensus price target of $248.70, suggesting a potential downside of 4.96%. Given Medpace's higher probable upside, equities analysts clearly believe Medpace is more favorable than Quest Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.23
Quest Diagnostics
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.56

78.0% of Medpace shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medpace$2.53B7.17$451.12M$18.0435.93
Quest Diagnostics$11.04B2.61$992M$10.0426.06

In the previous week, Quest Diagnostics had 24 more articles in the media than Medpace. MarketBeat recorded 28 mentions for Quest Diagnostics and 4 mentions for Medpace. Medpace's average media sentiment score of 1.50 beat Quest Diagnostics' score of 0.22 indicating that Medpace is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medpace
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Quest Diagnostics
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Medpace has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Summary

Medpace beats Quest Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Quest Diagnostics compare to AMN Healthcare Services?

Quest Diagnostics (NYSE:DGX) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Quest Diagnostics currently has a consensus price target of $248.70, indicating a potential downside of 4.96%. AMN Healthcare Services has a consensus price target of $39.17, indicating a potential downside of 1.19%. Given AMN Healthcare Services' higher possible upside, analysts clearly believe AMN Healthcare Services is more favorable than Quest Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quest Diagnostics
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.56
AMN Healthcare Services
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33

Quest Diagnostics has a net margin of 9.53% compared to AMN Healthcare Services' net margin of 3.10%. AMN Healthcare Services' return on equity of 23.42% beat Quest Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Quest Diagnostics9.53% 16.21% 7.41%
AMN Healthcare Services 3.10%23.42%7.19%

Quest Diagnostics has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$11.04B2.61$992M$10.0426.06
AMN Healthcare Services$2.73B0.56-$95.70M$2.7514.41

In the previous week, Quest Diagnostics had 21 more articles in the media than AMN Healthcare Services. MarketBeat recorded 28 mentions for Quest Diagnostics and 7 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.49 beat Quest Diagnostics' score of 0.22 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quest Diagnostics
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
AMN Healthcare Services
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Quest Diagnostics has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Quest Diagnostics beats AMN Healthcare Services on 11 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to Labcorp?

Quest Diagnostics (NYSE:DGX) and Labcorp (NYSE:LH) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Quest Diagnostics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Quest Diagnostics has higher earnings, but lower revenue than Labcorp. Quest Diagnostics is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$11.04B2.61$992M$10.0426.06
Labcorp$14.59B2.07$876.50M$12.1930.55

Quest Diagnostics has a net margin of 9.53% compared to Labcorp's net margin of 6.88%. Labcorp's return on equity of 17.13% beat Quest Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Quest Diagnostics9.53% 16.21% 7.41%
Labcorp 6.88%17.13%7.96%

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by insiders. Comparatively, 0.8% of Labcorp shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.3%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.8%. Quest Diagnostics pays out 34.3% of its earnings in the form of a dividend. Labcorp pays out 23.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Quest Diagnostics presently has a consensus price target of $248.70, indicating a potential downside of 4.96%. Labcorp has a consensus price target of $369.08, indicating a potential downside of 0.89%. Given Labcorp's stronger consensus rating and higher possible upside, analysts plainly believe Labcorp is more favorable than Quest Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quest Diagnostics
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.56
Labcorp
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83

In the previous week, Quest Diagnostics had 17 more articles in the media than Labcorp. MarketBeat recorded 28 mentions for Quest Diagnostics and 11 mentions for Labcorp. Labcorp's average media sentiment score of 0.34 beat Quest Diagnostics' score of 0.22 indicating that Labcorp is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quest Diagnostics
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Labcorp
4 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Labcorp beats Quest Diagnostics on 12 of the 19 factors compared between the two stocks.

How does Quest Diagnostics compare to CVS Health?

Quest Diagnostics (NYSE:DGX) and CVS Health (NYSE:CVS) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.3%. CVS Health pays an annual dividend of $2.66 per share and has a dividend yield of 3.0%. Quest Diagnostics pays out 34.3% of its earnings in the form of a dividend. CVS Health pays out 31.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 14 consecutive years and CVS Health has raised its dividend for 4 consecutive years. CVS Health is clearly the better dividend stock, given its higher yield and lower payout ratio.

Quest Diagnostics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, CVS Health has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 80.7% of CVS Health shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 0.9% of CVS Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, CVS Health had 12 more articles in the media than Quest Diagnostics. MarketBeat recorded 40 mentions for CVS Health and 28 mentions for Quest Diagnostics. CVS Health's average media sentiment score of 0.66 beat Quest Diagnostics' score of 0.22 indicating that CVS Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quest Diagnostics
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
CVS Health
15 Very Positive mention(s)
9 Positive mention(s)
10 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Positive

CVS Health has higher revenue and earnings than Quest Diagnostics. CVS Health is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$11.04B2.61$992M$10.0426.06
CVS Health$402.07B0.28$1.77B$8.5910.30

Quest Diagnostics currently has a consensus target price of $248.70, indicating a potential downside of 4.96%. CVS Health has a consensus target price of $107.33, indicating a potential upside of 21.29%. Given CVS Health's stronger consensus rating and higher probable upside, analysts clearly believe CVS Health is more favorable than Quest Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quest Diagnostics
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.56
CVS Health
0 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.92

Quest Diagnostics has a net margin of 9.53% compared to CVS Health's net margin of 2.62%. Quest Diagnostics' return on equity of 16.21% beat CVS Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Quest Diagnostics9.53% 16.21% 7.41%
CVS Health 2.62%13.65%4.20%

Summary

Quest Diagnostics and CVS Health tied by winning 10 of the 20 factors compared between the two stocks.

Get Quest Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DGX vs. The Competition

MetricQuest DiagnosticsHealthcare Providers & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$28.27B$10.63B$7.76B$22.92B
Dividend Yield1.32%2.54%2.46%3.79%
P/E Ratio25.5935.9734.2429.18
Price / Sales2.562.088.553.29
Price / Cash17.1123.3421.9315.51
Price / Book3.563.604.383.62
Net Income$992M$332.46M$3.52B$1.08B
7 Day Performance-0.47%-3.85%-5.33%-3.37%
1 Month Performance9.39%-1.57%-4.47%-2.11%
1 Year Performance38.03%19.09%-1.40%6.58%

Quest Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DGX
Quest Diagnostics
3.6776 of 5 stars
$256.93
-2.0%
$248.70
-3.2%
+40.0%$28.27B$11.04B25.5957,000
HSIC
Henry Schein
2.5875 of 5 stars
$88.41
+2.7%
$93.57
+5.8%
+18.9%$9.75B$13.18B24.2225,000
MEDP
Medpace
2.6493 of 5 stars
$672.93
+3.0%
$649.27
-3.5%
+9.8%$18.37B$2.53B36.416,200
AMN
AMN Healthcare Services
1.8347 of 5 stars
$38.00
+5.0%
$39.17
+3.1%
+150.5%$1.85B$2.73B13.722,664
LH
Labcorp
2.9718 of 5 stars
$371.68
+1.4%
$369.08
-0.7%
+39.6%$29.86B$13.95B20.3371,000

Related Companies and Tools


This page (NYSE:DGX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners